NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

Featured Updates to the NCCN Guidelines

View More View Less
  • 1 Roswell Park Comprehensive Cancer Center;
  • | 2 Mayo Clinic Cancer Center;
  • | 3 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • | 4 O'Neal Comprehensive Cancer Center at UAB;
  • | 5 City of Hope National Medical Center;
  • | 6 The University of Texas MD Anderson Cancer Center;
  • | 7 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 8 Memorial Sloan Kettering Cancer Center;
  • | 9 UCLA Jonsson Comprehensive Cancer Center;
  • | 10 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • | 11 University of Wisconsin Carbone Cancer Center;
  • | 12 Fred & Pamela Buffett Cancer Center;
  • | 13 Yale Cancer Center/Smilow Cancer Hospital;
  • | 14 Fox Chase Cancer Center;
  • | 15 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 16 Abramson Cancer Center at the University of Pennsylvania;
  • | 17 UC Davis Comprehensive Cancer Center;
  • | 18 Vanderbilt-Ingram Cancer Center;
  • | 19 University of Michigan Rogel Cancer Center;
  • | 20 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • | 21 Huntsman Cancer Institute at the University of Utah;
  • | 22 Moffitt Cancer Center;
  • | 23 University of Colorado Cancer Center;
  • | 24 Stanford Cancer Institute;
  • | 25 Massachusetts General Hospital Cancer Center;
  • | 26 UCSF Helen Diller Family Comprehensive Cancer Center;
  • | 27 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 28 Dana-Farber/Brigham and Women's Cancer Center;
  • | 29 Duke Cancer Institute;
  • | 30 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; and
  • | 31 National Comprehensive Cancer Network.

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.

  • 1.

    Tabbara IA, Robinson BE. Hematopoietic growth factors. Anticancer Res 1991;11:8190.

  • 2.

    Zhang X, Chuai Y, Nie W, et al. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev 2017;11:CD012035.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Soff GA, Miao Y, Bendheim G, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol 2019;37:28922898.

  • 4.

    Al-Samkari H, Parnes AD, Goodarzi K, et al. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica 2021;106:11481157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Shaw JL, Nielson CM, Park JK, et al. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 2021;106:662672.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Kiefel V. Reactions induced by platelet transfusions. Transfus Med Hemother 2008;35:354358.

  • 7.

    Al-Samkari H, Marshall AL, Goodarzi K, et al. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica 2018;103:e169172.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Miao J, Leblebjian H, Scullion B, et al. A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. Am J Hematol 2018;93:E86E88.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer 2014;22:12171222.

  • 10.

    Alkhouri N, Imawari M, Izumi N, et al. Lusutrombopag is safe and efficacious for treatment of thrombocytopenia in patients with and without hepatocellular carcinoma. Clin Gastroenterol Hepatol 2020;18: 26002608.e1.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Meng F, Chen X, Yu S, et al. Safety and efficacy of eltrombopag and romiplostim in myelodysplastic syndromes: a systematic review and meta-analysis. Front Oncol 2020;10:582686.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol 2018;5:e3443.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Al-Samkari H, Kolb-Sielecki J, Safina SZ, et al. Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo- controlled, phase 3 trial. Lancet Haematol 2022;9:e179189.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2020;26:e6573.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Gao F, Zhou X, Shi J, et al. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. Ann Hematol 2020;99:26792687.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Ahmed S, Bashir Q, Bassett R, et al. Eltrombopag for post-transplantation thrombocytopenia: results of phase II randomized, double-blind, placebo-controlled trial. Transplant Cell Ther 2021;27:430.e431430.e7.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 574 574 574
PDF Downloads 336 336 336
EPUB Downloads 0 0 0